 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Glaukos Corporation (GKOS) is an ophthalmic medical technology company.
The firm develops and commercializes products and procedures designed for the treatment of glaucoma. The company offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Its product pipeline comprises iStent Inject trabecular micro-bypass stent, which allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.
The company markets its products through direct sales force in the United States, Germany, Australia, and Canada, as well as through distribution partners in Europe, the Asia Pacific, and internationally.
Shares have formed a bullish "cup and handle" on several developments including positive review of the company's iStent Trabecular Micro-Bypass Stents, and positive comments from analysts on the stock and its revenue estimates. Higher share prices are expected for this stock.
52-Weeks Trading Range: $14.25 - $39.82
Entry Point: $38.30
Stop Loss: $36.10
Target Price: $42.10
GKOS closed at $35.00
